Hormonal
Apigenin, a natural flavonoid, ameliorates obesity-related inflammation and metabolic disorders by acting as a selective PPARγ modulator that promotes M2 macrophage polarization without causing the adverse side effects associated with full PPARγ agonists like rosiglitazone.
Apigenin, a flavonoid found in plants like chamomile and parsley, may help reduce obesity-related inflammation and improve metabolic health by modulating the PPARγ receptor. In mouse studies, it reduced inflammatory markers and improved liver and glucose metrics without the weight gain or bone loss seen with prescription drugs like rosiglitazone. While promising, these results are from animal models, and human dosing/effectiveness remains to be established.
Activation of PPARγ by apigenin blocks p65 translocation into nuclei through inhibition of p65/PPARγ complex translocation into nuclei, thereby decreasing NF-κB activation and favoring M2 macrophage polarization... Strikingly, apigenin reduces liver and muscular steatosis, decreases the levels of ALT, AST, TC and TG, improving glucose resistance obviously. Unlike rosiglitazone, apigenin does not cause significant weight gain, osteoporosis et al.
Why this rating
The study is conducted in murine models (HFD and ob/ob mice) and cell lines, not humans, limiting direct applicability to human clinical outcomes.
Source
Activation of PPARγ by a Natural Flavonoid Modulator, Apigenin Ameliorates Obesity-Related Inflammation Via Regulation of Macrophage Polarization
Xiujing Feng et al. · EBioMedicine · 2016
DOI 10.1016/j.ebiom.2016.06.017
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →